Brief: Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

LeonaBio

03/01/2024 12:16

Jan 3 (Reuters) - Athira Pharma Inc  ATHA.O :
    * ATHIRA PHARMA COMPLETES ENROLLMENT OF PHASE 2/3 LIFT-AD
CLINICAL
TRIAL OF FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S DISEASE
    * ATHIRA PHARMA INC - TOPLINE DATA FROM LIFT-AD ON TRACK FOR
SECOND HALF OF 2024

Source text for Eikon:  ID:nGNX43cKsF 
Further company coverage:  ATHA.O 

 ((Reuters.Briefs@thomsonreuters.com;))